Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + sintilimab + capecitabine
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Surufatinib + sintilimab + capecitabine is an investigational three-drug combination regimen. It is being evaluated in an investigator-initiated Phase Ib/II clinical trial (NCT05472948) for the treatment of previously treated metastatic small bowel adenocarcinoma (SBA) and appendiceal carcinoma. The regimen combines surufatinib, an oral small-molecule multi-kinase inhibitor targeting VEGFR1-3, FGFR1, and CSF-1R; sintilimab, a recombinant humanized IgG4 monoclonal antibody targeting PD-1; and capecitabine, an oral fluoropyrimidine carbamate chemotherapy that acts as a prodrug of 5-fluorouracil (5-FU). This combination aims to leverage the synergistic effects of anti-angiogenesis, CSF-1R-directed tumor microenvironment reprogramming, immune checkpoint blockade, and cytotoxic chemotherapy.
- Other names
- surufatinib + sintilimab + capecitabine regimensurufatinib and sintilimab in combination with capecitabinesurufatinib, sintilimab, and capecitabine
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)PDCD1 (Programmed cell death protein 1 receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)CSF1R (Macrophage colony-stimulating factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on surufatinib + sintilimab + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + sintilimab + capecitabine.